Skip Nav Destination
Idelalisib in the management of lymphoma
Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy
Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy
Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo
Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia
Issue Archive
July 21 2016
In this Issue
Table of Contents
BLOOD FLASHBACK
INSIDE BLOOD COMMENTARIES
PERSPECTIVES
BLOOD SPOTLIGHT
Idelalisib in the management of lymphoma
Clinical Trials & Observations
REVIEW ARTICLE
HOW I TREAT
CLINICAL TRIALS AND OBSERVATIONS
Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy
Clinical Trials & Observations
Vijay G. Bhoj,Dimitrios Arhontoulis,Gerald Wertheim,James Capobianchi,Colleen A. Callahan,Christoph T. Ellebrecht,Amrom E. Obstfeld,Simon F. Lacey,Jan J. Melenhorst,Farzana Nazimuddin,Wei-Ting Hwang,Shannon L. Maude,Mariusz A. Wasik,Adam Bagg,Stephen Schuster,Michael D. Feldman,David L. Porter,Stephen A. Grupp,Carl H. June,Michael C. Milone
HEMATOPOIESIS AND STEM CELLS
CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells
Amy Sinclair,Laura Park,Mansi Shah,Mark Drotar,Simon Calaminus,Lisa E. M. Hopcroft,Ross Kinstrie,Amelie V. Guitart,Karen Dunn,Sheela A. Abraham,Owen Sansom,Alison M. Michie,Laura Machesky,Kamil R. Kranc,Gerard J. Graham,Francesca Pellicano,Tessa L. Holyoake
IMMUNOBIOLOGY
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik,Tineke Casneuf,Inger S. Nijhof,Bie Verbist,Jaime Bald,Torben Plesner,Khaja Syed,Kevin Liu,Niels W. C. J. van de Donk,Brendan M. Weiss,Tahamtan Ahmadi,Henk M. Lokhorst,Tuna Mutis,A. Kate Sasser
LYMPHOID NEOPLASIA
Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy
Clinical Trials & Observations
Carmen Diana Herling,Marion Klaumünzer,Cristiano Krings Rocha,Janine Altmüller,Holger Thiele,Jasmin Bahlo,Sandra Kluth,Giuliano Crispatzu,Marco Herling,Joanna Schiller,Anja Engelke,Eugen Tausch,Hartmut Döhner,Kirsten Fischer,Valentin Goede,Peter Nürnberg,Hans Christian Reinhardt,Stephan Stilgenbauer,Michael Hallek,Karl-Anton Kreuzer
Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis
Efstathios Kastritis,Ioannis Papassotiriou,Evangelos Terpos,Maria Roussou,Maria Gavriatopoulou,Anna Komitopoulou,Chrysanthi Skevaki,Evangelos Eleutherakis-Papaiakovou,Constantinos Pamboucas,Erasmia Psimenou,Efstathios Manios,Stavroula Giannouli,Marianna Politou,Harikleia Gakiopoulou,Elektra Papadopoulou,Kimon Stamatelopoulos,Anna Tasidou,Meletios A. Dimopoulos
MYELOID NEOPLASIA
Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo
Brief Report
Ewa M. Kosciuczuk,Diana Saleiro,Barbara Kroczynska,Elspeth M. Beauchamp,Frank Eckerdt,Gavin T. Blyth,Sameem M. Abedin,Francis J. Giles,Jessica K. Altman,Leonidas C. Platanias
PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
TRANSPLANTATION
Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD
Benjamin M. Matta,Dawn K. Reichenbach,Xiaoli Zhang,Lisa Mathews,Brent H. Koehn,Gaelen K. Dwyer,Jeremy M. Lott,Franziska M. Uhl,Dietmar Pfeifer,Colby J. Feser,Michelle J. Smith,Quan Liu,Robert Zeiser,Bruce R. Blazar,Hēth R. Turnquist
Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience
Beatriz Morillo-Gutierrez,Rita Beier,Kanchan Rao,Lauri Burroughs,Ansgar Schulz,Anna-Maria Ewins,Brenda Gibson,Petr Sedlacek,Ladislav Krol,Brigitte Strahm,Irina Zaidman,Krzysztof Kalwak,Julie-An Talano,Ann Woolfrey,Chris Fraser,Isabelle Meyts,Ingo Müller,Jacek Wachowiak,Maria Ester Bernardo,Paul Veys,Karl-Walter Sykora,Andrew R. Gennery,Mary Slatter
LETTERS TO BLOOD
Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia
Clinical Trials & Observations
Alan K. Burnett,Nigel H. Russell,Robert K. Hills,on behalf of the United Kingdom National Cancer Research Institute Acute Myeloid Leukemia Study Group,on behalf of the United Kingdom National Cancer Research Institute Acute Myeloid Leukemia Study Group,on behalf of the United Kingdom National Cancer Research Institute Acute Myeloid Leukemia Study Group
Metabolic reprogramming of bone marrow stromal cells by leukemic extracellular vesicles in acute lymphoblastic leukemia
Suzanne M. Johnson,Clare Dempsey,Amy Chadwick,Stephanie Harrison,Jizhong Liu,Yujun Di,Owen J. McGinn,Marco Fiorillo,Federica Sotgia,Michael P. Lisanti,Mayur Parihar,Shekhar Krishnan,Vaskar Saha
BLOOD WORK
ERRATA
CONTINUING MEDICAL EDUCATION (CME) QUESTIONS
-
Cover Image
Cover Image
![issue cover]()
Normal plasma cells and humoral immunity persist following B-cell aplasia induced by CD19-directed chimeric antigen receptor (CAR) T-cell therapy. Immunohistochemistry of colonic tissue from a patient treated with CAR T-cell therapy targeting CD19 showing the presence of normal plasma cells expressing κ light chain. See the article by Bhoj et al on page 360.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
